share_log

Piper Sandler Reiterates Overweight on Skye Bioscience, Maintains $20 Price Target

Benzinga ·  Sep 21 01:57  · Ratings

Piper Sandler analyst Edward Tenthoff reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment